Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents

Fig. 1

Overall Survival. The median OS for all patients was 9.86 months. OS was higher in mCR patients (n = 7) than patients who did not reach mCR (n = 8): median 11.86 vs 8.67 months (HR = 0.28, p = 0.11), and longer than OS for patients with PD (n = 3, mOS = 3.15 months, HR = 0.23, p = 0.08). mCR = marrow complete remission; OS = overall survival; HR = hazard ratio; PD = progressive disease

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us